|

THE PLACEBO EFFECT
by Paul Petillo
Managing Editor,
BlueCollarDollar.com
May 1, 2007
Consider Dow 13,000. We
have already surpassed that mark and probably will do so repeatedly in
the next several weeks. To skeptics such as myself, there is an
underlying fallacy in numbers such as this. When DJIA hits new high
water marks, it allows investors to fall prey to the big number fallacy.
The
big number fallacy goes something like this: All big numbers, and we can
certainly qualify 13,000 as a big number in terms of stock market
advances, are considered infinite. There is the possibility that given
enough time the Dow could lumber on towards infinity. And the chartists
among us will agree, based on the pace of recent years that it could
happen in our lifetimes.
Most
would agree that the meteoric rise in that index of thirty industrials
that occurred from 1990 through two small recessions and a market
correction or two has been impressive. And as we further consider the
big number fallacy we find the Dow 13,000 is larger than any other
previous number and yet smaller than any other that may lie ahead and,
to complete the infinite fallacy, the numbers are the same as each
other. Being greater, less than and the same as is a feat that only
numbers can accomplish.
The
problem with such thinking is one of promotion. To most investors, big
numbers can only get bigger. In December of 2003, I offered readers of
this column the following suggestions when another big number was
broached. The excerpt was from an article titled the Kiss of Dow 10k.
“There
are still some worrisome indicators,”
I wrote suggesting that 10k might be just a smoke screen of sorts
masking deeper problems. “Right now though, it is important to think about how we should act,
what we should do, and how disastrous mistakes of the past can lead us
to profitable maneuvers in the future.”
You
will remember that many of us were still stinging from the losses we
experienced when the market seemingly fell from beneath our collective
feet and this article sought only to forewarn investors from jumping in.
It is a well-documented fact that investors like markets on the rise,
disdaining the bargains of a market on the decline.
“Many
of the pundits that I hear of late are encouraging trading in a market
that is moving steadily higher. Buying into such scenarios takes more
discipline than many people have. There are some simple guidelines you
can use though that will make any correction in equities (oops! the bear
in me is slipping out) less painful.”
To
this day I remain skeptical – invested mind you, but not so certain
that what we see is reality. My next suggestion sought to temper
enthusiasm but not discourage the human element involved.
“Once
you have made your decision to buy a certain stock, buy half as much as
you would like. Your exuberance has probably taken over your research
and trimming your enthusiasm for your decision is better done initially.
This market is trading at very high levels and in spite of all of the
potential, all of the growth, and all of the positive numbers, we have
come a long way too fast.”
And
that fact remains true today.
“There
are some technical problems with the markets right now. [A] Lack of
conviction means that money is simply moving around in as many issues as
possible, a spreading of risk that isn't necessarily something that
should be confused with diversification.
“Profits
at many companies are up based on lowered guidance as reported to
analysts. Underestimating profits is garrulous at best, lulling the
average investor to sleep while selling their own shares at record
levels.”
With
companies briskly repurchasing their own shares coupled with the hot
pursuit of potential leverage buyout candidates, the result, the current
reporting season has been grossly underestimated. And the Dow goes
higher.
Some
critics have challenged the Dow’ performance and questioned the
benchmark’s viability. The Dow is a price-weighted index giving member
companies with rising stock prices higher visibility or weight within
the index. As it crosses the 13,000 mark, only half of the Dow stocks
were up.
Compared
to the Dow, the S&P 500 has 347 advancing issues in an index that is
calculated based on market capitalization. And yet, the index has yet to
come close to the all-time closing high of 1,527.46 mark set in March
2000.
I
was equally critical of the Fed asserting that their failure to raise
interest rates was “timid”
and “has
allowed portfolio managers to run this economy.”
“And
lastly,”
I wrote, “productivity is not a
good indicator that things have improved. As many of the current work
force will tell you, excluding the temporary force that is shifting in
and out of the only jobs available, capacity to produce is strained to
human limits. When manufacturers begin to address this problem and
rehire workers to meet growing demand for increased inventories, stock
prices will begin to fall.”
In
this market, only three years later, manufacturing jobs have shifted to
service sector employment and in many instances for considerably less
pay. Capital spending, the kind that improves productivity has been
almost non-existent leaving many to wonder what is propelling these
outsized stock gains.
The
gross domestic product is down along with housing. Personal income is up
and spending is as well. The economy is down; consumer confidence is on
the wane. Regulators are threatening to throw SarbOx out as so much of a
knee-jerk reaction while 41% of the profits these companies are
reporting are coming from overseas operations. And the market shrugs.
While
I suggested that “the kiss of
10k would be mostly a peck on the cheek”. The intervening years
have led me to believe that rather than 13,000 being portrayed as the
love child of that kiss, it should be identified as more of a placebo
for an economy in trouble.
This
market offers little in the way of substance and a good deal in the way
of illusion. The Latin for placebo is “I shall please” and so the
market has. Portfolios and retirement savings plans have benefited from
the rise in stock prices. Those prices, acting as placebo, mean very
little without underlying growth.
It would
be wise to remember that in order for a placebo to work, there needs to
be faith in not only the person administering the treatment, the
markets, their cheerleaders, and the companies but the patient, the
investor as well. Do you have faith?

© 2007 Paul Petillo
Editorial Archive
CONTACT
INFORMATION
Paul Petillo
Blue Collar Dollar.com
Portland, OR USA
(501) 313-5252
Email
| Website
|